Sign in →

TEST ID DHTS Dihydrotestosterone, Serum

Reporting Name

Dihydrotestosterone, S

Specimen Type

Serum


Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

0.6 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
  Frozen  90 days
  Ambient  28 days

Special Instructions

Testing Algorithm

For more information see Steroid Pathways.

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

Portions of this test are covered by patents held by Quest Diagnostics

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK

Reference Values

Males

Cord blood: ≤100 pg/mL

≤6 months: ≤1,200 pg/mL

Tanner Stages

Mean

Age

Reference range (pg/mL)

Stage I (>6 months and prepubertal)

7.1 years

≤50

Stage II

12.1 years

≤200

Stage III

13.6 years

80-330

Stage IV

15.1 years

220-520

Stage V

18 years

240-650

>19 years: 112-955 pg/mL

 

Females

Cord blood: ≤50 pg/mL

≤6 months: ≤1,200 pg/mL

Tanner Stages

Mean

Age

Reference range (pg/mL)

Stage I (>6 months and prepubertal)

7.1 years

≤50

Stage II

10.5 years

≤300

Stage III

11.6 years

≤300

Stage IV

12.3 years

≤300

Stage V

14.5 years

≤300

20-55 years: ≤300 pg/mL

>55 years: ≤128 pg/mL

 

1. Pang S, Levine LS, Chow D, Sagiani F, Saenger P, New MI. Dihydrotestosterone and its relationship to testosterone in infancy and childhood. J Clin Endocrinol Metab. 1979;48(5):821-826

2. Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20(2):177-191

Day(s) Performed

Monday, Wednesday, Friday

Report Available

2 to 8 days

Specimen Retention Time

2 weeks

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

82642

Useful For

Monitoring patients receiving 5-alpha reductase inhibitor therapy or chemotherapy

 

Evaluating patients with possible 5-alpha reductase deficiency